Compare Delysium (AGI) vs Bio Protocol (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delysium vs Bio Protocol — how do they compare? Delysium trades at Rp47.29 (market cap Rp99,6M, Rp8,85M 24h volume), while Bio Protocol trades at Rp444.64 (market cap Rp1,01T, Rp168,57M 24h volume). The key difference: Bio Protocol is far larger — about 10140.6× Delysium's market cap, and Bio Protocol's supply is capped (2,3B / 3,3B BIO (69%)) while Delysium's keeps growing. Which is the better fit depends on your goals — on Pluang, investors hold Delysium for 17 Days and Bio Protocol for 18 Days on average.
| AGI | BIO | |
|---|---|---|
Market Cap | Rp99,6M | Rp1,01T |
Volume (24h) | Rp8,85M | Rp168,57M |
Circulating Supply | 2,1B AGI | 2,3B / 3,3B BIO (69%) |
Typical Hold Time | 17 Days | 18 Days |
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Delysium
Delysium is developing a blockchain-based collaboration network for AI Agents, centered around Lucy and the You Know I Love You (YKILY) Network. YKILY offers scalable, secure, and permissionless financial infrastructure for AI Agents, while Lucy, the first AI Agent on YKILY, serves as an AI-powered Web3 operating system that simplifies complex tasks through conversational workflows. Supported by industry leaders such as Microsoft, Google, Nvidia, and Y Combinator, Delysium is expanding an AI ecosystem that connects over 1.4 million digital wallets and aims to onboard more than 1 million AI Agents.
Read more on AGI →About Bio Protocol
BIO Protocol enables global communities of scientists, patients, and investors to collectively fund, develop, and co-own new drugs and therapeutics through its network of Biotech Decentralized Autonomous Organizations (BioDAOs). The protocol's innovative approach addresses critical gaps in traditional scientific funding, particularly in areas such as rare diseases, longevity research, and emerging health challenges.
Read more on BIO →
